Mario Javier Hitschfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mario Javier Hitschfeld has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ada Man-Choi Ho
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, USA
1 shared publication Alejandro Pattillo
Urogynecology Unit H. Dr. Sotero del Rio Santiago Chile
1 shared publication- Ariel Gorodischer
Department of Psychiatry, Universidad de los Andes, Santiago, Chile
1 shared publication Bernardita Blumel
Urogynecology Unit H. Dr. Sotero del Rio Santiago Chile
1 shared publication- Claudia Flores Espinoza
Escuela de Enfermería UC (Chile)
1 shared publication David J. Hinton
Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, Minnesota, 55905, USA
1 shared publication
Latest Publications
- Open Access
- 31 May 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-8
Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.
- 31 May 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-8
Open AccessMetabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.
- 2 May 2016
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 56 (4) , 391-397
Association between pelvic floor disorder symptoms and QoL scores with depressive symptoms among pelvic organ prolapse patients
Background: There is no consensus on the relationship between depressive symptoms (DS) and pelvic organ prolapse (POP) symptoms and quality of life (QoL). Our hypothesis was that women with DS and POP have worse symptoms and QoL than those without DS and POP.Aim: Our aim was to compare two groups of POP patients, those with depressive symptoms and those without, and evaluate the association of symptoms and QoL.Materials and methods: This planned report is part of a prospective study evaluating the impact of pessary use among symptomatic POP patients. Patients were evaluated by POP quantification (POP‐Q), pelvic ultrasound (US), voiding diaries, stress test, pad test, Pelvic Floor Distress Inventory (PFDI‐20), Prolapse QoL (P‐QoL) and the Goldberg Health Questionnaire (GHQ‐12) (psychological health screening for DS when score ≥5). A sample size of 78 patients was required to demonstrate a 50‐point difference in the global PFDI‐20 score with 80% power and 95% probability.Results: Ninety‐one women with POP were included. GHQ‐12 was positive in 47 (51.6%) patients. No differences were found in POP‐Q, pad and stress test between those with a positive GHQ‐12 and those without. However, GHQ‐12 was associated with higher PFDI‐20 scores and higher scores in seven of nine P‐QoL domains. GHQ‐12 persisted as an independent risk factor for worse P‐QoL scores after multivariable analysis.Conclusion: A ‘positive’ screening for DS was associated with worse PFDI‐20 and P‐QoL scores despite no difference in objective measurements. It may be that depressed patients interpret their symptoms differently.
- 2 May 2016
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 56 (4) , 391-397
Association between pelvic floor disorder symptoms and QoL scores with depressive symptoms among pelvic organ prolapse patients
Background: There is no consensus on the relationship between depressive symptoms (DS) and pelvic organ prolapse (POP) symptoms and quality of life (QoL). Our hypothesis was that women with DS and POP have worse symptoms and QoL than those without DS and POP.Aim: Our aim was to compare two groups of POP patients, those with depressive symptoms and those without, and evaluate the association of symptoms and QoL.Materials and methods: This planned report is part of a prospective study evaluating the impact of pessary use among symptomatic POP patients. Patients were evaluated by POP quantification (POP‐Q), pelvic ultrasound (US), voiding diaries, stress test, pad test, Pelvic Floor Distress Inventory (PFDI‐20), Prolapse QoL (P‐QoL) and the Goldberg Health Questionnaire (GHQ‐12) (psychological health screening for DS when score ≥5). A sample size of 78 patients was required to demonstrate a 50‐point difference in the global PFDI‐20 score with 80% power and 95% probability.Results: Ninety‐one women with POP were included. GHQ‐12 was positive in 47 (51.6%) patients. No differences were found in POP‐Q, pad and stress test between those with a positive GHQ‐12 and those without. However, GHQ‐12 was associated with higher PFDI‐20 scores and higher scores in seven of nine P‐QoL domains. GHQ‐12 persisted as an independent risk factor for worse P‐QoL scores after multivariable analysis.Conclusion: A ‘positive’ screening for DS was associated with worse PFDI‐20 and P‐QoL scores despite no difference in objective measurements. It may be that depressed patients interpret their symptoms differently.